Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christian K Behrens

Showing results (1-10 of 9) with videos related to

Pageof 1
Sort By:
European Journal of Immunology|September 30, 2003
The influence of CD95L expression on tumor rejection in miceFrederik H Igney, Christian K Behrens, Peter H Krammer
International Journal of Cancer|September 24, 2004
CD95L mediates tumor counterattack in vitro but induces neutrophil-independent tumor rejection in vivoFrederik H Igney, Christian K Behrens, Peter H Krammer
Current Opinion in Drug Discovery & Development|February 28, 2002
Transcriptomics in predictive toxicologyThorsten Storck, Marie-Charlotte von Brevern, Christian K Behrens, et al.
Plos One|June 7, 2013
Mapping the epitopes of a neutralizing antibody fragment directed against the lethal factor of Bacillus anthracis and cross-reacting with the homologous edema factorPhilippe Thullier, Arnaud Avril, Jacques Mathieu, et al.
Frontiers in Immunology|February 21, 2015
Selection of IgG Variants with Increased FcRn Binding Using Random and Directed Mutagenesis: Impact on Effector FunctionsCéline Monnet, Sylvie Jorieux, Rémi Urbain, et al.
Mabs|February 5, 2014
Combined glyco- and protein-Fc engineering simultaneously enhance cytotoxicity and half-life of a therapeutic antibodyCéline Monnet, Sylvie Jorieux, Nathalie Souyris, et al.
Plos One|January 26, 2011
Rise and fall of an anti-MUC1 specific antibodyHolger Thie, Lars Toleikis, Jiandong Li, et al.
Mabs|December 18, 2014
The human Müllerian inhibiting substance type II receptor as immunotherapy target for ovarian cancer. Validation using the mAb 12G4Nathalie Kersual, Véronique Garambois, Thierry Chardès, et al.
British Journal of Haematology|February 28, 2008
Chronic lymphocytic leukaemia cells are efficiently killed by an anti-CD20 monoclonal antibody selected for improved engagement of FcgammaRIIIA/CD16Christophe de Romeuf, Charles-Antoine Dutertre, Magali Le Garff-Tavernier, et al.
Pageof 1

Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
European Journal of Immunology|September 30, 2003
The influence of CD95L expression on tumor rejection in miceFrederik H Igney, Christian K Behrens, Peter H Krammer
International Journal of Cancer|September 24, 2004
CD95L mediates tumor counterattack in vitro but induces neutrophil-independent tumor rejection in vivoFrederik H Igney, Christian K Behrens, Peter H Krammer
Current Opinion in Drug Discovery & Development|February 28, 2002
Transcriptomics in predictive toxicologyThorsten Storck, Marie-Charlotte von Brevern, Christian K Behrens, et al.
Plos One|June 7, 2013
Mapping the epitopes of a neutralizing antibody fragment directed against the lethal factor of Bacillus anthracis and cross-reacting with the homologous edema factorPhilippe Thullier, Arnaud Avril, Jacques Mathieu, et al.
Frontiers in Immunology|February 21, 2015
Selection of IgG Variants with Increased FcRn Binding Using Random and Directed Mutagenesis: Impact on Effector FunctionsCéline Monnet, Sylvie Jorieux, Rémi Urbain, et al.
Mabs|February 5, 2014
Combined glyco- and protein-Fc engineering simultaneously enhance cytotoxicity and half-life of a therapeutic antibodyCéline Monnet, Sylvie Jorieux, Nathalie Souyris, et al.
Plos One|January 26, 2011
Rise and fall of an anti-MUC1 specific antibodyHolger Thie, Lars Toleikis, Jiandong Li, et al.
Mabs|December 18, 2014
The human Müllerian inhibiting substance type II receptor as immunotherapy target for ovarian cancer. Validation using the mAb 12G4Nathalie Kersual, Véronique Garambois, Thierry Chardès, et al.
British Journal of Haematology|February 28, 2008
Chronic lymphocytic leukaemia cells are efficiently killed by an anti-CD20 monoclonal antibody selected for improved engagement of FcgammaRIIIA/CD16Christophe de Romeuf, Charles-Antoine Dutertre, Magali Le Garff-Tavernier, et al.
Pageof 1